2149P - Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)

Background

Catheter-related thrombosis (CRT) is the most frequent non-infectious complication regarding central venous devices (CVC). Its incidence has been reported 13% and 66% in symptomatic and asymptomatic patients, respectively, with several factors influencing its development.

Methods

CRT events recorded at TESEO between 2018 and 2023 were assessed. Descriptive and association analysis for rethrombosis and bleeding regarding location of thromboembolic event (TE) was conducted.

Results

A total of 245 patients developed CRT. Mean age was 60.5 years (SD 12.3). Ninety-one percent were ECOG ≤1. Most prevalent comorbidities were HTA (28.6%) and dyslipidemia (28.2%), with other TE-associated risk factors being ≤10%. PICC was present in 42.1%, PAC in 40.9% while 17% were missing. Previous VTE was present in 9.8% of patients, while 4.5% and 4.4% were on antiplatelet and anticoagulation therapy, respectively. Colorectal and breast cancers were the primary locations in 26.9% and 21.2%. Metastatic disease was observed in 54.3%. Cytotoxic chemotherapy was used in 80.4%, radiotherapy in 22.9% and 53.9% had the primary tumor resected. PE was present in 6.5%, being clinically suspected in 56.2% of cases. The diagnosis was mainly unilateral (81.3%) and 50% were central. VTE – related symptoms occurred in 70.2% of cases at presentation. LMWH was used in 91% and hospital admission was advised in 20.8% of cases. VTE – related complications were observed in 2%, being PE and superior vena cava syndrome the most frequent (40%). Arterial and venous rethrombosis were present in 0.8% and 4.9%. Minor bleeding episodes occurred in 2.5% of cases, while major/clinically relevant episodes were present in 3.6%. There was no association between rethrombosis and TE location (pulmonary embolism (PE) vs deep vein thrombosis (DVT), OR 2.57 (95% CI 0.52 – 12.6; p = 0.245)). An increased risk for major and minor bleeding was observed for PE compared to DVT (OR 6.58 (95% CI 1.8 – 23.7)).

Conclusions

Usual TE – associated risk factors were infrequent. CRT was symptomatic in most cases, with reduced complication rates after treatment. A probable association of bleeding risk and no differences for rethrombosis were observed for PE events.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Sociedad Española de Oncología Médica.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.